D M Patel Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.71 M
- Company Age 19 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 10.54%
- Profit Growth 0.04%
- Ebitda 10.71%
- Net Worth 7.25%
- Total Assets 20.10%
About D M Patel Pharma
D M Patel Pharma Private Limited (DMPPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 April 2005 and has a history of 19 years and ten months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.71 M, as per Ministry of Corporate Affairs (MCA) records.
Manoj Patel, Jignesh Patel, and Mahendra Patel serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230MH2005PTC152428
- Company No.
152428
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Apr 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does D M Patel Pharma Private Limited offer?
D M Patel Pharma Private Limited offers a wide range of products and services, including Herbal Oil, Ayurvedic Pain Relief Oil.
Who are the key members and board of directors at D M Patel Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Patel  | Director | 05-Apr-2005 | Current |
| Jignesh Patel | Director | 05-Apr-2005 | Current |
| Mahendra Patel | Director | 05-Apr-2005 | Current |
Financial Performance of D M Patel Pharma.
D M Patel Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 10.54% increase. The company also saw a slight improvement in profitability, with a 0.04% increase in profit. The company's net worth moved up by a moderate rise of 7.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of D M Patel Pharma?
In 2020, D M Patel Pharma had a promoter holding of 44.64% and a public holding of 55.36%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at D M Patel Pharma?
Unlock and access historical data on people associated with D M Patel Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of D M Patel Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D M Patel Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.